Editorial: Advances in chronic ischemic cerebrovascular disease: diagnosis and management
Nico Sollmann,Yu Lei,Michael E. Sughrue
DOI: https://doi.org/10.3389/fneur.2024.1440175
IF: 3.4
2024-11-30
Frontiers in Neurology
Abstract:Ischemic cerebrovascular diseases relate to a variety of large vessel and small vessel angiopathies, which are common causes of ischemic stroke and cognitive dysfunction especially in the elderly population [1; 2; 3; 4; 5]. Although complex pathologic processes and high rates of morbidity make ischemic cerebrovascular diseases challenging to treat, new clinical evidence continues to emerge for improved understanding of such diseases. Currently, basic and clinical research focusses on modified treatment approaches to accelerate the understanding of the disease, to improve patient care and monitoring, and, ultimately, to reduce patient morbidity and mortality, with application of advanced neuroimaging techniques being used for biomarker development and testing in this regard [6; 7; 8; 9; 10]. Furthermore, recent major topics focused on aspects of advanced brain function, given that chronic ischemic conditions are also increasingly recognized as relevant risk factors for clinically silent brain infarctions and cognitive impairment [11; 12; 13; 14]. Two studies of the Research Topic investigated patients with Moyamoya disease (MMD) [15; 16]. Specifically, MMD is a cerebrovascular disorder with typically progressive steno-occlusive disease predominantly involving the bilateral intracranial internal carotid artery (ICA) together with the proximal branches [17; 18]. The disease is mainly observed in Japan, whereas the incidence in other parts of the world is rather low [17; 19; 20]. The disease can entail symptoms related to brain ischemia (e.g., stroke) and/or related to compensatory mechanisms that can occur in response to ischemia (e.g., hemorrhage from fragile collateral vessels) [17; 18]. In the report by Cao et al., hemodynamic abnormalities in 42 patients with MMD were examined before and after intervention by combined revascularization (i.e., surgery involving a direct superficial temporal artery-middle cerebral artery bypass and an indirect encephalo-arterio-synangiosis bypass) using intraoperative FLOW800, a specialized software utilizing indocyanine green video-angiography to analyze data and generate color delay mapping [16]. The courses of parameters and associations between intraoperative FLOW800 and color Doppler ultrasonography (CDUS) measurements were evaluated, showing that both the intraoperatively measured delay time (i.e., the time interval between 0 and 50% of maximum fluorescence intensity for FLOW800 analysis) and rise time (i.e., the time interval between 10 and 90% of the maximum fluorescence intensity for FLOW800 analysis) substantially decreased in the recipient artery and vein [16]. Microvascular transit time from intraoperative assessment was significantly reduced after surgery, and all postoperatively collected parameters from CDUS exhibited significant changes in comparison to the preoperative state [16]. Significant associations between microvascular transit time, resistance index, and pulsatility index were observed [16]. Based on the finding that hemodynamic outcomes of the donor and recipient arteries demonstrated significant changes following bypass surgery, the authors concluded that the parameter of time may be more precise and sensitive for assessment of hemodynamics using FLOW800, while multiple evaluations of hemodynamics could offer beneficial data for perioperative management in MMD [16]. In the study by Yu et al., metabolites associated with MMD were investigated by means of liquid chromatography coupled with mass spectrometry (LC-MS) to discern metabolic biomarkers in cerebrospinal fluid (CSF) samples [15]. The patient group consisted of 16 patients with MMD, which were compared to a healthy control group of 8 subjects [15]. The CSF samples were obtained during bypass surgery in the patient group and from lumbar puncture (during lumbar anesthesia) in the control group [15]. Overall, 129 significant differential metabolites in the CSF samples were identified when comparing the MMD patients to the healthy controls, which were associated with multiple pathways (e.g., purine metabolism and pyrimidine metabolism, amongst other pathways) [15]. Hence, utilizing an LC-MS-based metabolomics approach may hold promise for enhancing the clinical diagnosis of MMD, and the identified parameters may lead to developments of novel diagnostic markers for MMD regarding the pathogenesis of the disease [15]. Three articles published as part of the Research Topic focused on stroke regarding diagnostics or treatment [21; 22; 23]. Acute stroke is defined by an acute onset of focal neurological deficits stemming from affection of one or more vascular territories of the brain, which can manifest due to loss of blood supply due to ischemic or hemorrhagic stroke [24; 25; 26]. Besides neurological assessment, the diagnostic approach commonly includes imaging of the brain parenchyma, brain-feeding arteries, and oftentimes perfusion imaging using com -Abstract Truncated-
neurosciences,clinical neurology